London, England, United Kingdom
Ebenezer is a leading Health Economist, A.I. and Machine Learning Developer. He is a leading Health Economist and Market Access professional with multi-country multi-therapy area experience. Ebenezer has led diverse teams of technical and commercial teams to successfully obtain reimbursement approval and strong market access for a number of pharmaceutical products in areas including Oncology, Hepatitis C, Diabetes, and Eye Care. He has worked in the EU5, US, Japan, and developed solutions for pharma emerging markets. Ebenezer has -Proven track record of impact in leading positions in complex, multi-stakeholder organisations and academic environments. -Evidence of strategic thinking and vision, with the ability to analyse complex concepts and information and communicating it effectively to external stakeholders in a way that is meaningful to them. -External representation and influencing of stakeholders including government. Collaborating with other organisations internationally. -Proven senior management experience at an international level, but with the ability to work in an entrepreneurial, small business environment.
Health Economist and market access professional • Successfully led team to create SLR, NMA, economic models, and reports for certolizumab pegol (Cimzia), an anti-TNF drug indicated for psoriasis. Cimzia received approval for reimbursement by NICE. • Clients have included Pfizer, Gilead, AstraZeneca, Bristol-Myers Squibb, Lundbeck, UCB, Parexel, Deloitte, NHS England, United Health, Optum Insight. • Worked on multiple diseases: Non-Small Cell Lung Cancer (NSCLC), Breast Cancer, Acute Myeloid Leukemia, Hepatitis C, Chronic Kidney Disease, Crohn's Disease, Psoriasis, Psoriatic Arthritis, Cerebral Palsy, Cystic Fibrosis, Endometriosis, Major Depressive Disorder, and Preterm Labour and Birth. • Model specification documents, cost-effectiveness and budget impact models, and reports to both HTA and non-HTA countries including the US, EU5, Sweden, Norway, Malaysia, China, and Japan. • Managed relationship with clinical experts, pharmaceutical clients, and other economists in the project team. • Successfully created many cost-effectiveness and budget impact models/model adaptions in Excel and VBA, and Javascript. Implemented full Markov Models, Semi Markov Models – using area-under-the-curve analysis, Decision Trees, PSA and DSA sensitivity analysis. Taught and coached members of the team on VBA and Excel. • Created value proposition and strategy for medical devices companies focussed on mental health and treatment adherence. Rolling out product and services across 80 CCGs in England. • Used Real-World Evidence to convince CCGs to commission new services for 1.4 million people in England. • Successfully led negotiations of a nanotechnology delivery system for oncology products valued at $150mln. Further created commercialisation strategy of said product. Responsible for -Defining strategy -Client relationship management -Organic people growth -Scaling businesses
I train SMEs to understand reimbursement in the UK, Europe, and globally. I also speak with young people to accelerate their progress or to prevent harmful life choices.
Supported global and affiliate market access strategies across eye care (retina, glaucoma, dry eye disease) and immunology (pediatric psoriasis and polyarticular juvenile idiopathic arthritis - pcJIA). Led development of early economic models and HTA-ready cost-utility models — from conceptualization and structural design through to full implementation and adaptation for local submissions. Delivered payer-relevant evidence and models for anti-VEGF treatments, gene therapies, and their competitors, including surgical implants, ensuring comprehensive coverage of therapeutic landscapes. Partnered with affiliates to prepare robust pricing and reimbursement dossiers, aligned with payer requirements across multiple markets. Conducted evidence synthesis through network meta-analyses (NMAs) and matching-adjusted indirect comparisons (MAICs) to inform comparative effectiveness and value narratives. Collaborated with external vendors to commission new CUAs and adapted global models to meet local HTA needs. Analyzed real-world evidence databases (Medisoft, Vestrum, medical claims) to generate insights into treatment patterns, disease burden, and healthcare resource use. Contributed to advisory boards, presenting models and engaging with KOLs and payers to validate assumptions and refine submissions. Worked cross-functionally with market access, pricing, clinical, regulatory, and medical affairs teams, ensuring economic evidence was integrated throughout the asset lifecycle
• Responsible for leading HEOR activities globally in oncology for a number of solid tumours in Esophageal cancer, Hepatocellular carcinoma, and breast indications • Worked with senior leaders across Market Access, Pricing, and Medical Affairs to create a unified aligned launch strategy. • Sourced global and local vendors to execute HEOR activities in utility values for major markets, creating global economic models – CEMs and BIMs, creating global ITCs, adapting models for affiliates, and assisting affiliates in submissions and subsequent questions from HTA authorities • Created tools with assisted markets with negotiations when economic models were not strictly required • Mentored junior members of the team. Created project trackers for senior leaders and partners across the company. • Submitted a number of abstracts to ISPOR with manuscripts under review
Head of HEOR with responsibilities across rare/orphan diseases and drugs including -business development -leading client engagement -training and coaching junior and senior members of department -mid year and final year review of departmental staff -technical upskilling of team -part of renumeration committee -part of recruitment committee -part of marketing committee
Country Lead and Associate Director for Health Economics and Real World Evidence to support Market Access activities for Abicipar, Atogepant, Botox, Brazikumab, Brimonidine, Cenicriviroc, Ozurdex, Rapastinel, Relamorelin, and XEN. This includes • Supporting HTA submissions • Providing country-specific input on the selection of Patient-Reported Outcomes (PROs) for interventional trials and observational studies. • Consulting and advising the global teams on clinical study endpoints, statistical analysis plans for health economics and outcomes research, and using the resulting data in creating compelling evidence for payers for their country • Leading the development and customization of local health economic and budget impact models, leveraging all available research in alignment with global programs • Ensuring the health economics and outcomes research program is aligned to the international commercial strategy • Selecting and working with study vendors to assist in the execution of the local HEOR programs, including budget management. Assuming overall accountability for the vendor deliverables • Supporting HTA/Payer/Government interactions in the country • Project managing the delivery of all RWE studies including concept documents, proposals, protocols, statistical analysis plans (SAP) and reports. Outcomes of studies supported publications, market access, and HTAs.